title: No association of antibodies to glutamic acid decarboxylase and diabetic complications in patients with IDDM.
abstract: OBJECTIVE
  To evaluate the association of antibodies to glutamic acid decarboxylase (GAD-ab) and diabetic complications (neuropathy, retinopathy, and nephropathy) in patients with insulin-dependent diabetes mellitus (IDDM).
  
  
  METHODS
  We examined the prevalence of GAD-ab (immunoprecipitation assay) and islet cell antibodies (ICAs) (indirect immunofluorescence) in a representative sample of IDDM patients (n = 146) with different disease duration (2-52 years, median 13.2 years). Of all patients characterized for the existence of diabetic complications, 56 of 146 had peripheral neuropathy, 24 of 142 had autonomic neuropathy, 67 of 141 had retinopathy, and 39 of 146 had nephropathy.
  
  
  RESULTS
  GAD-ab (> 2 SD) were detected more frequently than ICA (> 5 Juvenile Diabetes Foundation units) in IDDM patients of different disease duration (GAD-ab+ 37% [54 of 146] vs. ICA+ 22% [32 of 146], P = 0.011; diabetes duration less than median: GAD-ab+ 47% vs. ICA+ 23%, P = 0.0046; diabetes duration greater than median: GAD-ab+ 27% vs. ICA+ 22%, P > 0.05). For GAD-ab and for ICA, respectively, no difference was observed in frequency of positivity or titers between patients with or without diabetic complications.
  
  
  CONCLUSIONS
  Both GAD-ab and, to a lesser extent, ICA persist for a long time in several individuals. This persistence is not related to diabetic neuropathy or any other diabetic complication.
authors.affiliation: Diabetes Research Institute, Schwabing City Hospital, Munich, Germany.
authors.forename: U
authors.initials: U
authors.lastname: Roll
authors.forename: A
authors.initials: A
authors.lastname: Nuber
authors.forename: A
authors.initials: A
authors.lastname: Schröder
authors.forename: E
authors.initials: E
authors.lastname: Gerlach
authors.forename: H U
authors.initials: HU
authors.lastname: Janka
authors.forename: A G
authors.initials: AG
authors.lastname: Ziegler
mesh_terms: D000293:Adolescent; D000328:Adult; D001323:Autoantibodies / Q000097:blood*; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000276:immunology* / Q000503:physiopathology*; D003928:Diabetic Nephropathies / Q000453:epidemiology* / Q000276:immunology; D003929:Diabetic Neuropathies / Q000453:epidemiology* / Q000276:immunology; D003930:Diabetic Retinopathy / Q000453:epidemiology* / Q000276:immunology; D005260:Female; D005968:Glutamate Decarboxylase / Q000097:blood*; D006801:Humans; D007515:Islets of Langerhans / Q000276:immunology; D008297:Male; D008875:Middle Aged; D011507:Proteinuria; D011897:Random Allocation; D013997:Time Factors
chemical_list: D001323:Autoantibodies; C024211:islet cell antibody; D005968:Glutamate Decarboxylase